Drug profile · INN
mephenytoin
MESANTOIN
mephenytoin (MESANTOIN) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.
Drug details — mephenytoin
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
mephenytoin (MESANTOIN) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Primary target: Sodium channel alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is mephenytoin?
mephenytoin (MESANTOIN) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for mephenytoin?
MESANTOIN is a marketed brand name for mephenytoin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of mephenytoin?
mephenytoin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.